ATNM Investors Invited to Participate in Actinium Pharmaceuticals, Inc. Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American: ATNM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Actinium Pharmaceuticals, Inc. (ATNM)
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Shareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) should contact Levi & Korsinsky about Securities Fraud Investigation - ATNM
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
Shareholder Rights Advocates at Levi & Korsinsky Investigate Actinium Pharmaceuticals, Inc. (ATNM) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Actinium Pharmaceuticals, Inc. (ATNM)
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– ATNM
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
An Investigation Has Commenced on Behalf of Actinium Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ATNM Losses.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge
U.S. stocks traded lower toward the end of trading, with the S&P 500 dipping more than 100 points on Monday.
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
On Monday, the FDA determined that Actinium Pharmaceuticals, Inc.'s ATNM Phase 3 SIERRA trial is not adequate to support a Biologics License Application (BLA) filing for Iomab-B despite its statistically significant primary endpoint.
